Celdoxome pegylated liposomal Evrópusambandið - íslenska - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doxórúbicín hýdróklóríð - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Æxlishemjandi lyf - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Fluenz Evrópusambandið - íslenska - EMA (European Medicines Agency)

fluenz

medimmune llc - reassortant inflúensu veira (lifandi, bæklaða) eftir stofnar:a/kaliforníu/7/2009 (h1n1)pdm09 eins og stofn, a/victoria/361/2011 (h3n2) eins og stofn, b/massachusetts/2/2012 eins og álag - influenza, human; immunization - bóluefni - fyrirbyggjandi meðferð inflúensu hjá einstaklingum 24 mánaða til yngri en 18 ára. notkun fluenz ætti að vera byggt á opinberum tillögur.

Fluenz Tetra Evrópusambandið - íslenska - EMA (European Medicines Agency)

fluenz tetra

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - inflúensu, manna - inflúensu bóluefni, inflúensu, lifandi, bæklaða - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. notkun fluenz tetra ætti að byggjast á opinberum ráðleggingum.

Intrinsa Evrópusambandið - íslenska - EMA (European Medicines Agency)

intrinsa

warner chilcott uk ltd. - testósterón - kynferðisleg truflun, sálfræðileg - hormón kynlíf og stillum kynfæri - intrinsa er ætlað fyrir meðferð hypoactive kynhvöt röskun (hsdd) í tvíhliða oophorectomised og hysterectomised (skurðaðgerð völdum tíðahvörf) konur fá aðra estrógen meðferð.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Evrópusambandið - íslenska - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant inflúensu veira (lifandi, bæklaða) eftir álag: a/víetnam/1203/2004 (h5n1) álag - inflúensu, manna - bóluefni - fyrirbyggjandi inflúensu í opinberlega lýst faraldur ástandið í börn og unglingar frá 12 mánuði til að minna en 18 ára aldri. faraldur inflúensu h5n1 astrazeneca ætti að vera notuð í samræmi við opinbera leiðsögn.

Treo Citrus Freyðitafla 500/50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

treo citrus freyðitafla 500/50 mg

viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500/50 mg

Treo Freyðitafla 50 mg/ 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

treo freyðitafla 50 mg/ 500 mg

viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 50 mg/ 500 mg

Treo Hindbær Freyðitafla 500/50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

treo hindbær freyðitafla 500/50 mg

viatris aps - coffeinum; acidum acetylsalicylicum - freyðitafla - 500/50 mg

Treo Freyðitafla 500 mg/50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

treo freyðitafla 500 mg/50 mg

viatris aps - acidum acetylsalicylicum; coffeinum - freyðitafla - 500 mg/50 mg

DuoPlavin Evrópusambandið - íslenska - EMA (European Medicines Agency)

duoplavin

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - blóðþurrðandi lyf - duoplavin er ætlað til að koma í veg fyrir beinþrýstingslækkandi aukaverkanir hjá fullorðnum sjúklingum sem taka bæði klópídógrel og asetýlsalisýlsýru (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. nánari upplýsingar er að vísa til kafla 5.